As the company enters the next stage of growth we will focus on advancing the awareness of our scientific technology platform and continue our revolutionary innovation in functional precision medicine,” said Laurie Heilmann, CEO of Notable. “It’s an exciting time to join the talented team at Notable. Prior to CrownBio, Laurie held leadership roles at Strong-Bridge Consulting, Image Metrix-American College of Radiology and the Ockham Development Group. Her efforts helped transform the company into a prominent global player in the pre-clinical oncology, cardiovascular, and metabolic disease markets. She joins Notable from CrownBio, where she served as President of Global Life Science and Diagnostic Solutions and led the strategic development and commercialization of products and services to treat oncology, cardiovascular, and metabolic diseases. Heilmann brings more than 30 years of executive leadership experience. We will continue to expand the reach of our technology to power functional precision medicine with Laurie at the helm.” “Notable’s experienced and diverse team has spent over five years focused on developing our clinical platform and building partnerships with top academic institutions and leading pharmaceutical companies. We are delighted to welcome her to the team during this critical inflection point in our trajectory,” said Matt De Silva, Founder and Executive Chairman. “Laurie has a proven track record transforming life science startups into established global brands. She succeeds founder Matt De Silva who will remain a member of Notable’s Board of Directors and continue to serve as the company’s Executive Chairman. FOSTER CITY, CA – Ap(GLOBE NEWSWIRE) - Notable, a technology leader redefining cancer treatment through rapid drug development via a clinically validated platform, announced today its board has appointed veteran life science executive Laurie Heilmann as Chief Executive Officer.
0 Comments
Leave a Reply. |